Home » Stocks » PRVB

Provention Bio, Inc. (PRVB)

Stock Price: $14.53 USD -0.69 (-4.53%)
Updated Jan 25, 2021 4:00 PM EST - Market closed
Market Cap 954.87M
Revenue (ttm) n/a
Net Income (ttm) -76.55M
Shares Out 56.34M
EPS (ttm) -1.52
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 25
Last Price $14.53
Previous Close $15.22
Change ($) -0.69
Change (%) -4.53%
Day's Open 15.22
Day's Range 13.91 - 15.30
Day's Volume 1,698,401
52-Week Range 5.42 - 19.45

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 6 days ago

BILTHOVEN, Netherlands, Jan. 19, 2021 /PRNewswire/ -- Intravacc, a world leader in translational research and development of vaccines, today announced that a candidate polyvalent inactivated c...

PRNewsWire - 1 week ago

RED BANK, N.J., Jan. 13, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announce...

PRNewsWire - 1 week ago

RED BANK, N.J., Jan. 12, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announce...

Zacks Investment Research - 1 week ago

Investors need to pay close attention to Provention Bio (PRVB) stock based on the movements in the options market lately.

Seeking Alpha - 2 weeks ago

Provention Bio is focused on slowing down, or actually preventing in some cases, the onset of autoimmune conditions. Provention's first therapeutic, teplizumab, looks set for approval in mid-2...

PRNewsWire - 2 weeks ago

RED BANK, N.J., Jan. 6, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced ...

PRNewsWire - 3 weeks ago

RED BANK, N.J., Jan. 4, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced ...

PRNewsWire - 1 month ago

RED BANK, N.J., Dec. 21, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced...

PRNewsWire - 1 month ago

RED BANK, N.J., Dec. 15, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced...

PRNewsWire - 2 months ago

RED BANK, N.J., Nov. 11, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, today announced that...

Seeking Alpha - 2 months ago

Provention Bio, Inc. (PRVB) CEO Ashleigh Palmer on Q3 2020 Results - Earnings Call Transcript

PRNewsWire - 2 months ago

RED BANK, N.J., Nov. 5, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, today reported financ...

Seeking Alpha - 2 months ago

Provention is leading a set of new drugs that protect beta cell functions, enabling endogenous insulin production in type 1 diabetes patients. The stock may have a PDUFA late next year; rollin...

PRNewsWire - 2 months ago

RED BANK, N.J., Nov. 2, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, today announced the c...

PRNewsWire - 2 months ago

RED BANK, N.J., Oct. 29, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, today announced that...

PRNewsWire - 3 months ago

RED BANK, N.J., Oct. 1, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq:PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, yesterday launched a n...

PRNewsWire - 3 months ago

RED BANK, N.J., Sept. 30, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announce...

Zacks Investment Research - 4 months ago

Investors need to pay close attention to Provention Bio (PRVB) stock based on the movements in the options market lately.

PRNewsWire - 4 months ago

RED BANK, N.J., Sept. 8, 2020 /PRNewswire/ -- Provention Bio, Inc.

PRNewsWire - 4 months ago

OLDWICK, N.J., Aug. 31, 2020 /PRNewswire/ -- Provention Bio, Inc.

The Dog of Wall Street - 4 months ago

Under looked biotech company might be near tipping point

The Motley Fool - 5 months ago

Each of these companies has the potential to generate life-changing returns.

Other stocks mentioned: VRTX
PRNewsWire - 5 months ago

OLDWICK, N.J., Aug. 11, 2020 /PRNewswire/ -- Provention Bio, Inc.

Seeking Alpha - 5 months ago

Provention Bio, Inc. (PRVB) CEO Ashleigh Palmer on Q2 2020 Results - Earnings Call Transcript

PRNewsWire - 5 months ago

OLDWICK, N.J., Aug. 6, 2020 /PRNewswire/ -- Provention Bio, Inc.

Seeking Alpha - 5 months ago

Provention Bio: Undervalued And Overlooked Biotech Company - Diabetes Is Not Going Away Anytime Soon

The Motley Fool - 6 months ago

Provention Bio is developing a drug that could delay the onset of diabetes, and if it's successful, the company's stock could soar.

PRNewsWire - 6 months ago

OLDWICK, N.J., June 30, 2020 /PRNewswire/ -- Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced toda...

PRNewsWire - 7 months ago

OLDWICK, N.J., June 22, 2020 /PRNewswire/ -- Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced toda...

PRNewsWire - 7 months ago

OLDWICK, N.J., June 17, 2020 /PRNewswire/ -- Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announce...

The Motley Fool - 7 months ago

The company announced a public offering of common stock.

PRNewsWire - 7 months ago

OLDWICK, N.J., June 16, 2020 /PRNewswire/ -- Provention Bio, Inc., (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announce...

Zacks Investment Research - 7 months ago

Provention Bio (PRVB) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

The Motley Fool - 7 months ago

The company released positive data from a clinical trial for one of its pipeline candidates.

The Motley Fool - 7 months ago

The company released positive data from a clinical trial for one of its pipeline candidates.

PRNewsWire - 7 months ago

OLDWICK, N.J., June 15, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced ...

PRNewsWire - 7 months ago

OLDWICK, N.J., May 28, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced ...

PRNewsWire - 8 months ago

OLDWICK, N.J., May 20, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, t...

PRNewsWire - 8 months ago

OLDWICK, N.J. and TAMPERE, Finland, May 18, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune...

Seeking Alpha - 8 months ago

Provention Bio, Inc. (PRVB) CEO Ashleigh Palmer on Q1 2020 Results - Earnings Call Transcript

Benzinga - 8 months ago

When it comes to treating chronic, immune-mediated diseases, the standard course is to wait for symptoms before beginning treatment.

Seeking Alpha - 9 months ago

Provention Bio: The First Type 1 Diabetes Breakthrough In A 100 Years

Zacks Investment Research - 9 months ago

Provention Bio (PRVB) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Seeking Alpha - 9 months ago

Provention Bio: Discounted Price, Insider Buying, And Catalysts Frame The Opportunity

The Motley Fool - 10 months ago

Efforts to stem the coronavirus outbreak are liable to disrupt the protocols of a lot of drug trials.

The Motley Fool - 10 months ago

The decision was made to protect the safety of those involved.

Seeking Alpha - 10 months ago

Provention Bio, Inc. (PRVB) CEO Ashleigh Palmer on Q4 2019 Results - Earnings Call Transcript

Seeking Alpha - 10 months ago

Provention Bio: A Buy On Type 1 Diabetes Opportunity And Clear Path To Approval

Seeking Alpha - 11 months ago

Provention Bio: A Promising Small-Cap Immuno-Endocrinology Player For 2020

The Motley Fool - 1 year ago

It's a $45 billion market -- here are some winners that could keep winning.

Other stocks mentioned: DXCM, LVGO

About PRVB

Provention Bio, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, an oral CSF-1R inhibitor, which is in Phase IIa clinical trial for the treatment of Crohn's disease; PRV-3279, which has completed Phase 1b clinical trial for the treatment of lupus;... [Read more...]

Industry
Biotechnology
CEO
Ashleigh Palmer
Employees
19
Stock Exchange
NASDAQ
Ticker Symbol
PRVB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for Provention Bio stock is "Strong Buy." The 12-month stock price forecast is 29.00, which is an increase of 99.59% from the latest price.

Price Target
$29.00
(99.59% upside)
Analyst Consensus: Strong Buy